Movement Alert｜KEYMED BIO-B Intraday Rise 11.1% in Regular Trading, third-quarter revenue of Kangyueda reached about RMB660 million with 227% growth

On October 16, KEYMED BIO-B rose 11.1% intraday in Regular Trading, trading at HK$84.6, with turnover of HK$100 million.

The immediate catalyst was the company’s disclosure that revenue from core product Kangyueda totaled about RMB660 million in the first three quarters, up about 227% year on year.

The company said the growth was driven by genuine market demand and a sharp increase in hospital admissions coverage. It also disclosed that in July the product was formally included in the National Essential Medicines List, effective September 1. Earlier updates showed the drug had already been included in the national reimbursement drug list from January 1 for three approved indications and two formulations, with a reimbursement standard of RMB1,039 per unit, supporting faster commercialization.

Additional context from prior disclosures showed first-half Kangyueda sales of RMB393 million, up 132%, while brokers had recently highlighted rapid volume ramp-up and maintained positive ratings on commercialization and pipeline progress.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)